Navigation Links
Cambrex Reports Fourth Quarter and Full Year 2010 Results
Date:2/10/2011

he expectations the Company describes in its forward-looking statements, including but not limited to, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation and regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, changes in foreign exchange rates, uncollectable receivables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, and the Company's ability to receive regulatory approvals for its products.

For further details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex 2009 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the U.S. Securities and Exchange Commission.  

About CambrexCambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  We offer Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products.  For more information, please visit www.cambrex.com.   CAMBREX CORPORATIONStatements of Profit and LossFor the Quarters Ended December 31, 2010 and 2009(in thousands)20102009% of% ofAmountSalesAmountSalesGross Sales

$

63,522100.0%$

58,709100.0%Commissions, Allowances and Rebates3410.5%7791.3%Net Sales63,18199.5%57,93098.7%Other Revenues1,7272.7%(63
'/>"/>

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Wins 2009 Silver Innovation Award
2. Cambrex to Announce Third Quarter 2009 Financial Results on November 3, 2009
3. Cambrex Reports Third Quarter 2009 Results
4. Cambrex Acquires IEP GmbH
5. Cambrex to Announce Third Quarter 2010 Financial Results on November 3, 2010
6. Cambrex Acquires Stake in Zenara Pharma
7. Cambrex Zenara Supplies Product for Launch of Nicorette® in India
8. Shawn P. Cavanagh Appointed Chief Operating Officer of Cambrex
9. Cambrex Zenara Manufacturing Facility Receives European GMP Approval
10. Cambrex to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), a ... products for the treatment of central nervous system disorders, ... Vanda,s President and CEO, will deliver a corporate presentation ... New York City on Thursday, June 4, ... presentation at the Jefferies Global Healthcare Conference will be ...
(Date:6/2/2015)... International plc (NASDAQ: ENDP ) (TSX: ENL) (the ... an underwritten public offering of $1.75 billion of ordinary ... are to be sold by Endo. ... the Offering an option, exercisable for a period of ... supplement, to purchase an additional $262.5 million of ordinary ...
(Date:6/2/2015)... STATESVILLE, N.C. , June 2, 2015 ... its Board of Directors declared a quarterly cash dividend ... 26, 2015 to stockholders of record at the close ... About Kewaunee Scientific Founded in 1906, Kewaunee ... design, manufacture, and installation of laboratory, healthcare, and technical ...
Breaking Medicine Technology:Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares 2Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares 3Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares 4
... BOSTON, Dec. 29, 2011  Solos Endoscopy, Inc. (OTCPK: SNDY) ... continued growth in 2012 through the development and sales ... treatment and management of medical conditions. In 2011, Solos ... approximately $300,000 in debt for the Company. The signed ...
... Dec. 29, 2011 Janssen Research & Development, LLC (JRD) ... Application (sNDA) to the U.S. Food and Drug Administration (FDA) ... an oral anticoagulant, to reduce the risk of (thrombotic) cardiovascular ... The filing is supported by data from the pivotal Phase ...
Cached Medicine Technology:Solos Endoscopy, Inc. is Primed for Growth in 2012 2Solos Endoscopy, Inc. is Primed for Growth in 2012 3Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 2Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 3Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 4Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 5Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 6Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 7Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 8Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 9Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 10Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 11
(Date:6/2/2015)... Aidan Booth And Steve Clayton's ... yesterday, and has since received rave reviews from ... Tiffany Hendricks has weighed in with her opinion ... on her website HonestyFirstReviews.com. , "These days the ... looking to hone their business skills has gotten ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Food Lion ... its sixth annual “Thriller on the Griller” events, starting ... and South Carolina locations. Each event will raise funds ... to restoring a sense of self, restoring the family ... our military families. , Through these events, Food ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 MEDIA ... Wallace, 571-319-9594 (cell) , Email: ewallace(at)mentalhealthamerica(dot)net , Breaking ... New Mental Health Legislation at MHA Annual Conference ... What: Rep. Murphy to address the Mental Health ... the long-awaited updated version of the Helping Families ...
(Date:6/2/2015)... April 8th, 2015, saw the transformation ... Entertainment’s “RockNRolla Movie Awards” EcoLuxe Lounge, a daylong event, ... of the world’s top providers of ecologically sound and ... by Debbie Durkin, Los Angeles’ leading producer of sustainable ... is a premier red carpet event that makes appearances ...
(Date:6/2/2015)... 2015 On March 19th, 2015, LiveToBeSober.org ... the Hall of Legends at Detroit’s Ford Field. Hosted ... Herman Moore, the goal of the conference was to ... society, highlight the benefits of effective professional rehabilitation programs. ... the options that are available to them in regards ...
Breaking Medicine News(10 mins):Health News:100K Factory - Review of Aidan Booth and Steve Clayton's New IM System Published 2Health News:Food Lion to Launch “Thriller on the Griller” Events to Benefit Military Families through Hope For The Warriors® 2Health News:Food Lion to Launch “Thriller on the Griller” Events to Benefit Military Families through Hope For The Warriors® 3Health News:Congressman Tim Murphy to Unveil Details of New Mental Health Legislation at MHA Annual Conference Thursday 2Health News:Choices Recovery South Bend Discusses Addiction With Rising Hollywood Star Ben Stillwell 2Health News:Rehabilitation Facility Graduate Shares Her Story at "Fighting Addiction Together" Conference 2
... teachers and students prefer enhanced sex education programs//, they ... UK schools. When teen pregnancy is taken into consideration, ... officials said. The study, which was conducted by the ... Medical Journal, covered about 25 secondary schools. ...
... of Parliament tuesday that she would resign if the ... by March 2007. ,Her comment was ... select committee who were apprehensive about the NHS's half-year ... NHS trusts are forecasting deficits. The deficits are expected ...
... over the effects of drinking too much alcohol on their ... While alcohol-related deaths have doubled in last 15 years, just ... last 3 months, worried about the effects of over drinking ... exercise and too much stress – says Legal & General. ...
... type of salmonella bacteria.It is usually found in eggs infected ... bacteria is now found more often in chicken meat. Tests ... increase of salmonella enteritidis on chicken meat., ,Salmonella is ... year with an annual death toll of about 600 in ...
... play an important role in how insects develop from ... model for congestive heart failure// to be effective in ... rhythms, according to UC Davis research published in the ... Academy of Sciences. ,The research, led by cardiologist ...
... includes products like insulin, sugar-free food and healthcare books, ... 'D' Lounge has been set up by Way-to-Health, a ... ,"'D' Lounge offers a complete range of products ... biscuits, jams and honey. Sugar-free toothpaste is also available ...
Cached Medicine News:Health News:Insect Protein Effective for Treating Heart Enlargement, Arrythmias 2
Angled for temporal approach. Solid 14 mm blades. Dull finish....
Open 11 mm blades. Polished finish....
Open 10 mm blades. Dull finish....
Angled for temporal approach. Open 14 mm rounded blades for patient comfort. Dull finish....
Medicine Products: